Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib

Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone

(2021) Lloyd Wei Tat Tang et al.   MOLECULAR PHARMACOLOGY

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor

(2020) Ellen Scheers et al.   XENOBIOTICA

Erdafitinib: First Global Approval

(2019) Anthony Markham   DRUGS

LC-MS/MS determination of erdafitinib in human plasma after SPE: Investigation of the method greenness

(2019) Tarek Elawady et al.   MICROCHEMICAL JOURNAL

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

(2017) Timothy P.S. Perera et al.   MOLECULAR CANCER THERAPEUTICS

Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites

(2016) Aneesh Karkhanis et al.   BIOCHEMICAL PHARMACOLOGY

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

(2016) Young Kwang Chae et al.   Oncotarget

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib

(2015) Han Kiat Ho et al.   DRUG METABOLISM REVIEWS

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Mechanism-Based Inactivation of Cytochromes by Furan Epoxide: Unraveling the Molecular Mechanism

(2013) Nikhil Taxak et al.   INORGANIC CHEMISTRY

New Oral Anticoagulants and the Cancer Patient

(2013) N. J. Short et al.   ONCOLOGIST

Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks

(2012) Suvi T. M. Orr et al.   JOURNAL OF MEDICINAL CHEMISTRY

Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib

(2011) Pei-pei Dong et al.   ACTA PHARMACOLOGICA SINICA

Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

(2010) E. M. Haugsten et al.   MOLECULAR CANCER RESEARCH

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

(2010) W. C. Teng et al.   MOLECULAR PHARMACOLOGY

Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants

(2007) Thomas M. Polasek et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY